Tatva Chintan Pharma Chem Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹167Cr
- +42.7% YoY
- +24.6% QoQ
- Net profit
- ₹16Cr
- +128.6% YoY
- +60% QoQ
- Margin
- 19%
- +4 pp YoY
- −2 pp QoQ
Guidance rank: #32 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
Tatva Chintan expects a revenue CAGR of 20-25% over the next 3-4 years driven by new and existing products. Tatva Chintan expects a 20% to 25% compounded annual growth rate (CAGR) in revenue over the next 3 to 4 years.
From Tatva Chintan Pharma Chem Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- Tatva Chintan expects a revenue CAGR of 20-25% over the next 3-4 years driven by new and existing products.
- Q1 FY27 saw a 43% year-on-year revenue growth and 25% sequential increase, indicating strong momentum.
- Phase Transfer Catalysts and Structure Directing Agents (SDA) segments show robust demand expansion, supported by Euro 7 implementation and wider market acceptance.
- Electrolyte Salts segment is expected to contribute around 10% of revenue in FY27, with gradual ramp-up driven by hybrid vehicle battery commercialization post-2026.
- The company plans a greenfield capacity expansion to boost future revenue potential by INR300 crores at peak utilization.
2 more points from Tatva Chintan Pharma Chem Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Tatva Chintan Pharma Chem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Tatva Chintan has a planned greenfield capex of INR 200 crores for FY27 aimed at scaling up R&D-ready products and catering to domestic demand.
- The new multiproduct facility will support pharma and agro intermediates, electrolytes, SDA, and other sectors, with an expected peak revenue of around INR 300 crores.
- This facility is planned to be operational within 18 to 21 months, addressing expected growth beyond INR 800-850 crores revenue.
- The company is also focusing on debottlenecking and continuous flow chemistry upgrades in existing plants to optimize capacity.
2 more points from Tatva Chintan Pharma Chem Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Tatva Chintan Pharma Chem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Tatva Chintan does not maintain a traditional order book with confirmed orders.
- Orders are generally received and fulfilled on a quarter-on-quarter basis.
- Customer demand is described as very visible and highly clear.
2 more points from Tatva Chintan Pharma Chem Ltd's call on order book
Create a free account to keep reading this call
Tatva Chintan Pharma Chem Ltd — Quarterly revenue & net profit
Tatva Chintan Pharma Chem Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 167 | 117 | +42.7% | 134 | +24.6% |
| Operating profit (EBITDA) | 32 | 17 | +88.2% | 28 | +14.3% |
| Operating margin | 19% | 15% | +4 pp | 21% | -2 pp |
| Profit before tax | 21 | 9 | +133.3% | 17 | +23.5% |
| Net profit (PAT) | 16 | 7 | +128.6% | 10 | +60% |
| EPS (₹) | 6.83 | 2.84 | +140.5% | 4.41 | +54.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹217 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Tatva Chintan's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Alufluoride (Q1 FY27)
Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr
- POCL Enterprises (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
- Devson Catalyst (Q1 FY27)
FY 2023-24: ₹5,577.59 Lakhs . Key investor presentation takeaways from Devson Catalyst Ltd's Q1 FY27 investor presentation — and how it ranks against sector pee
- Ambani Orgochem (Q1 FY27)
Financial highlights show Total Income in ₹ Lakhs: . Key investor presentation takeaways from Ambani Orgochem's Q1 FY27 investor presentation — and how it ranks
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Tatva Chintan Pharma Chem Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Tatva Chintan Pharma Chem Ltd Q1 FY27 results?
Tatva Chintan expects a revenue CAGR of 20-25% over the next 3-4 years driven by new and existing products. Tatva Chintan expects a 20% to 25% compounded annual growth rate (CAGR) in revenue over the next 3 to 4 years.
What is Tatva Chintan Pharma Chem Ltd share price analysis?
Tatva Chintan Pharma Chem Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 79.0 with a market cap of ₹4,141 Cr. Investors should review the full earnings analysis for detailed insights.
Is Tatva Chintan Pharma Chem Ltd planning capital expenditure?
Tatva Chintan has a planned greenfield capex of INR 200 crores for FY27 aimed at scaling up R&D-ready products and catering to domestic demand.
Keep Tatva Chintan Pharma Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
